AccuDx CQ Triple Marker – CKMB/Myo/TnI (25 Test)

AccuDx CQ Triple Marker – CKMB/Myo/TnI (25 Test)

(1 customer review)

30,000.00

Overview

Buy AccuDx Triple Marker

CK-MB/cTnI/yo Fast Test Kit

(Immunofluorescence Assay) used for determination of CK-MB/cTnl/Myoin serum, plasma or whole blood.

Triple marker test is used as an aid in the clinical diagnosis, prognosis and evaluation of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome. Kit contains: ACCUDx CQ CK-MB/CTnI/Myo test card in a sealed pouch with desiccant 25, Disposable pipet, Whole blood buffer, SD/RFID card, User manual, Whole blood buffer composition: Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

 

 

5 in stock

About

AccuDx Triple Marker CK-MB/cTnI/yo Fast Test Kit (Immunofluorescence Assay) is intended for in vitro quantitative determination of CK-MB/cTnl/Myoin serum, plasma or whole blood. This test is used as an aid in the clinical diagnosis, prognosis and evaluation of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome.

Creatine kinases are dimer isozymes composed of two monomer subunits, CK-M (for skeletal muscle derived) and CK-B (for brain derived), which can form al three combinations of monomers: CK-BB, CK-MM, and CK-MB. BB is found primarily in the brain. Skeletal muscles primarily contain the MM isoform, with trace amount of MB (around 1-4% of total CK activity). Cardiac muscles also contain the MM isoform, but higher amount of MB, typicaly around 20% of total CK activity. CK-MB is a more sensitive marker of myocardial injury than total CK activity, because it has a lower basal level and a much narrower normal range. Medical literatures commonly state that CK-MB levels are elevated in 4 to 6 hours, peak at 10 to 24 hours, and return to normal within 3 to 4 days after an acute myocardial infarction. Classically, an increase of the myocardial-specific enzyme CK-MB is considered as the hallmark of acute myocardial infarction, and increased levels are frequently interpreted by the clinician as objective evidence of myocardial cell damage. Troponin complex consists of three regulatory proteins: T, which connects the troponin complex and tropomyosin (another cardiac muscle regulatory protein); I, which prevents muscle contraction in the absence of calcium; and C, which binds calcium. Cardiac troponin 1 (MW 22.5 kDa) and the two skeletal muscle isoforms of troponin I have considerable amino acid sequence homology, but cT contains an additional N-terminal sequence and is highly specific for myocardia.
Clinical studies have demonstrated the release of cTnl into the blood stream within hours following acute myocardial infarctions (AM) or ischemic damage. Elevated levels of cTnl are detectable in blood within 4 to 6 hours after the onset of chest pain, reaching peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. Due to the high myocardial specificity and the long duration of elevation, cTnl has become an important marker in the diagnosis and evaluation of patients
suspected of having an AMl. Myoglobin is a small monomeric protein which serves as an intracellular oxygen storage site. It is found in abundance in the muscle and can get through into the blood circulation directly when myocardial cell is damaged mildly. Therefore, myoglobin has been advocated as a sensitive marker fo early acute myocardial injury by American College of Cardiology Committee.

Specification

Mixed monoclonal antibodies against human CK-MB, cT and Myo are conjugated with fluorescence latex and another set of anti-human CK-MB/cTnI/Myo monoclonal antibodies were coated on different test lines respectively. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human CK-MB, cTnl and My monoclonal antibodies will bind with the CK-MB, cTnl and Myo in sample respectively and form marked antigen-antibody complexes. These complexes move to the test card detection zone by capillary action. Then marked antigen-anti- body complexes will be captured on different test lines by another set of
monoclonal antibodies against human CK-MB, cT or Myo respectively resulting in the accumulation of fluorescence particles on the test lines. The fluorescence intensity of each test line increases in proportion to the amount of CK-MB, cTnl or Myo in sample.
Then insert test card into ACCUDx CQ Immunofluorescence Quantitative Analyzer, the concentration of CK-MB, cT and Myo in sample will be measured and displayed on the screen. The value will be stored in ACCUDX CQ Analyzer and available for downloading. The result can be easily transmitted to LIS and HIS.

CONTENTS
1. ACCUDx CQ CK-MB/cTnl/Myo kit contains:

  • ACCUDx CQ CK-MB/CTnI/Myo test card in a sealed pouch with desiccant 25
  • Disposable pipet
  • Whole blood buffer
  • SD/RFID card
  • User manual

2. Whole blood buffer composition: Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

3. A test card consists of: A plastic shell and a reagent strip which is composed of a sample pad, nitrocellulose membrane (one end of the membrane is coated with fluorescence latex-]abelled anti-human CK-MB. cTnl and Myo monoclonal antibodies, these three lines are coated with another anti-human CK-MB another anti-human cTnl and another anti-human My monoclonal antibody,
respectively, and the control line C is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits.

Applicable Device:
ACCUDx CQ Immunofluorescence Quantitative Analyzer

 

Safety Information

PRECAUTIONS:

1. For in vitro diagnostic use only.

2. For professional use only.

3. Do not use the kit beyond the expiration date.

4. Do not use the test card if the foil pouch is damaged.

5. Do not open pouches until ready to perform the test.

6. Do not reuse the test card.

7. Do not reuse the pipet.

8. Handle all specimens as potentially infectious. Proper handling anddisposal methods should be followed in accordance with local regulations.

9. Carefully read and follow the manual to ensure proper test performance.

Direction for Use

TEST PROCEDURE
1. Collect specimen according to manual.
2. Test card, sample and reagent should be brought to roomtemperatureprior to testing.
3. Confirm SD card lot No. in accordance with test kit lot No.. Perform“SDCard Calib” calibration when necessary (Details refer to 8.5.2of
Getein1100 User Manual).
4. On the main interface of Getein1100, press “”ENT”” button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver 100 μl of sample into one tube of sample diluent, mix gently and thoroughly. Then drop 100 μl (or 3dropsof sample when using disposable pipet) of sample mixture into thesampleport on the test card.
8. After 10 minutes, insert the test card into Getein1100 and press “”ENT””button. The result will be shown on the screen and”

Other Info

Store the test card at 4~30oC with a valid period of 24 months.
Use the test card within 1 hour once the foil pouch is opened.
Store the blood sample diluent at 0~30oC with a valid period of 24 months.
Store the blood sample diluent at 2~8oC for better results.

1 review for AccuDx CQ Triple Marker – CKMB/Myo/TnI (25 Test)

  1. Mandar Kale

    Accurate result

Add a review

Your email address will not be published. Required fields are marked *

Fill Captcha *Time limit exceeded. Please complete the captcha once again.

×

Hello!

Click below to chat with us on WhatsApp

×